Capstone Financial Advisors Inc. Sells 862 Shares of Pfizer Inc. (NYSE:PFE)

Capstone Financial Advisors Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 8.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,085 shares of the biopharmaceutical company’s stock after selling 862 shares during the period. Capstone Financial Advisors Inc.’s holdings in Pfizer were worth $241,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Northern Trust Corp increased its position in Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock valued at $1,548,889,000 after buying an additional 4,167,222 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Pfizer by 0.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 4,836,488 shares of the biopharmaceutical company’s stock valued at $128,312,000 after buying an additional 13,681 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Pfizer during the 4th quarter valued at about $53,000. Criteria Caixa S.A.U. acquired a new position in Pfizer during the 4th quarter valued at about $47,909,000. Finally, Shorepoint Capital Partners LLC increased its position in Pfizer by 44.3% during the 4th quarter. Shorepoint Capital Partners LLC now owns 96,156 shares of the biopharmaceutical company’s stock valued at $2,551,000 after buying an additional 29,511 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group decreased their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research note on Tuesday, April 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.57.

Pfizer Stock Performance

NYSE:PFE opened at $22.95 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a fifty day moving average of $24.58 and a two-hundred day moving average of $25.92. The stock has a market capitalization of $130.16 billion, a PE ratio of 16.28, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.49%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is presently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.